Effectiveness of Intramuscular Aripiprazole Injection in Patients with Catatonia: Report on Three Cases

 

 Buy Article Permissions and Reprints

In the recent literature, orally administered aripiprazole, a second generation antipsychotic, was demonstrated to be effective in the resolution of catatonia. Our present paper is the first report of three cases of catatonia where intramuscularly administered high doses of aripiprazole were found to be effective in resolving severe catatonic states, independent of the features, or of the origin of catatonia, presenting either in schizophrenia or in major depression. On the basis of the unique mechanism of action of the drug and based on our clinical experience, we recommend the use of high doses of intramuscular aripiprazole as an alternative treatment for catatonia, when benzodiazepines or electroconvulsive therapy are not effective or not proposed.

References

• 1 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press Inc. 2000
  PubMed
• 2 Bastiampillai T, Dhillon R. Catatonia resolution and aripiprazole.  Austral New Zeal J Psychiatry. 2008;  12 907
  PubMedGoogle Scholar
• 3 Bush G, Fink M, Petrides G. et al . Rating scale and standardized examination.  Acta Psychiatr Scand. 1996;  93 9-136
  CrossrefPubMedGoogle Scholar
• 4 Caroff SN, Mann SC, Francis A. et al .eds Catatonia: From psychopathology to neurobiology. American Psychiatric Publishing Inc. 2004
  PubMed
• 5 Fink M, Taylor MA. eds Catatonia: A clinician's guide to diagnosis and treatment. Cambridge (UK): Cambridge University Press 2003
  PubMed
• 6 Freeman B, Levy W, Gorman JM. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.  J Psychiatr Pract. 2007;  13 120-124
  CrossrefPubMedGoogle Scholar
• 7 Huffman J, Fricchione G. Catatonia and psychosis in a patient with AIDS: treatment with lorazepam and aripiprazole.  J Clin Psychopharmacol. 2006;  25 508-510
  PubMedGoogle Scholar
• 8 Hung GC, Chen YY. Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient.  Pharmacopsychiatry. 2007;  40 83-84
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology.  J Neural Transm. 2002;  109 1453-1467
  CrossrefPubMedGoogle Scholar
• 10 Philbrick KL, Rummans TA. Malignant catatonia.  J Neuropsychiatry Clin Neurosci. 1999;  6 1-13
  PubMedGoogle Scholar
• 11 Sheldrick AJ, Gründer G. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis.  Pharmacopsychiatry. 2008;  41 160
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Strawn JR, Delgado SV. Successful treatment of catatonia with aripiprazole in an adolescent with psychosis.  J Child Adolesc Psychopharmacol. 2007;  17 733-735
  CrossrefPubMedGoogle Scholar
• 13 Van Den Eede F, Van Hecke J, Van Dalfsen A. et al . The use of atypical antipsychotics in the treatment of catatonia.  Eur Psychiatry. 2005;  20 422-429
  CrossrefPubMedGoogle Scholar
• 14 World Health Organization .The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva (Switzerland): World Health Organization 1992
  PubMed

Correspondence

V. VorosMD 

Department of Psychiatry and Psychotherapy

University of Pecs

7623 Pecs

Ret u. 2

Hungary

Phone: +36/725/35 900

Fax: +36/725/35 951

Email: viktor.voros@aok.pte.hu